Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

ALENDRONATE & CHOLECALCIFEROL

All products: general benefit

Other products in the same Health Canada class (M05B) — coverage varies; not interchangeable

  • Alendronate (Fosamax): general benefit, Not a benefit
  • Risedronate (Actonel DR): general benefit, Not a benefit
  • Clodronate (Ostac): limited Use 280, 358, 359, Not a benefit
  • Denosumab (Stoboclo): limited Use 686, Limited Use 687, 688
  • Etidronate (Didronel): limited Use 236, 237, Not a benefit
  • Zoledronic acid (Aclasta): limited Use 319, 436, 523, Not a benefit

1 more in the class list below

Fosavance · DIN 02276429 · 70mg & 70mcg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists Fosavance (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Fosavance · DIN 02276429 Manufacturer: Organon Canada Inc.; listing date 2007-01-02 Health Canada: Marketed since 2022-06-29 · brand FOSAVANCE · ATC M05BB03 ALENDRONIC ACID AND CHOLECALCIFEROL, M05BB03 ALENDRONIC ACID AND CHOLECALCIFEROL · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM TRIHYDRATE) 70 MG, VITAMIN D3 (CHOLECALCIFEROL) 2800 UNIT · company Organon canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $2.4348 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76210 · Verify on the e-Formulary ↗ (DIN 02276429)

Source record
DIN 02276429: Fosavance Raw flags: chronicUseMed=Y, sec3=Y Item: 920000544; group id 892; item number 2142; lccId None; manufacturer id OCI Source form: Tab; strength: 70mg & 70mcg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $5.5335; ministry $2.4348 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02276429 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76210 Therapeutic Notes (formulary) Note: The recommended dose of Vitamin D for osteoporosis prevention and treatment in adults over 50 years old is at least 800 IU/day, in conjunction with calcium. This product does not provide the total recommended daily intake of Vitamin D; supplemental Vitamin D may be required. The appropriate dosage of ALENDRONATE & CHOLECALCIFEROL must be determined by the physician based on the patient's vitamin D requirement.
Interchangeable products
Apo-Alendronate/Vitamin D3 · DIN 02454467 · $2.4348 Jamp Alendronate/Vitamin D3 · DIN 02519828 · $2.4348
Shortage status: resolved shortage (ended 2025-10-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02276429
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

ALENDRONATE

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab

RISEDRONATE SODIUM

· 23 products · General benefit (20), Listed, not a benefit (3) · strengths: 35mg, 5mg, 30mg, 150mg · DR Tab, Tab

CLODRONATE DISODIUM

· 2 products · Listed, not a benefit (1), Limited Use, codes 280, 358, 359 (1) · strengths: 400mg · Cap

DENOSUMAB

· 8 products · Limited Use, codes 687, 688 (4), Limited Use, codes 686 (4) · strengths: 60mg/mL, 120mg/1.7mL · Inj Sol-1.0mL Pref Syr Pk (Preservative-Free), Inj Sol-Pref Syr, Inj Sol-Pref Syr (Preservative-Free), Inj Sol-Vial Pk, Inj Sol-Vial Pk (Preservative-Free)

ETIDRONATE DISODIUM

· 2 products · Listed, not a benefit (1), Limited Use, codes 236, 237 (1) · strengths: 200mg · Tab

ZOLEDRONIC ACID

· 12 products · Limited Use, codes 319, 436, 523 (2), Off-Formulary Interchangeable, not an ODB benefit (10) · strengths: 5mg/100mL, 4mg/5mL · Inj Sol-100mL Pk (Preservative-Free), Inj Sol-5mL Pk (Preservative-Free)

PAMIDRONATE DISODIUM

· 9 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 3mg/mL, 6mg/mL, 9mg/mL · Inj Sol-10mL Vial

ALLOPURINOL

· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab

AMANTADINE HCL

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

BROMOCRIPTINE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab

CLOPIDOGREL BISULFATE

· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 92:00 and 75 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: osteoporosis in men, osteoporosis in postmenopausal women
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. RISEDRONATE SODIUM · General benefit (20), Listed, not a benefit (3) For the prevention of osteoporosis in postmenopausal women who are at risk of developing osteoporosis, ACTONEL preserves or increases BMD at sites of clinical importance. PM: https://pdf.hres.ca/dpd_pm/00068139.PDF; date NOV 3, 2022; DIN 02246896; fetched 2026-09-10 Product monograph  the treatment of osteoporosis in men, to improve bone mineral density PM: https://pdf.hres.ca/dpd_pm/00068139.PDF; date NOV 3, 2022; DIN 02246896; fetched 2026-09-10 Product monograph  The treatment of osteoporosis in postmenopausal women PM: https://pdf.hres.ca/dpd_pm/00068139.PDF; date NOV 3, 2022; DIN 02246896; fetched 2026-09-10 Product monograph RALOXIFENE HCL · Limited Use, codes 373 INDICATIONS AND CLINICAL USE APO-RALOXIFENE (raloxifene hydrochloride) is indicated for the treatment and prevention of osteoporosis in postmenopausal women. PM: https://pdf.hres.ca/dpd_pm/00002184.PDF; date not captured; DIN 02279215; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS FOSAVANCE® (alendronate sodium/cholecalciferol) is indicated for: • The treatment of osteoporosis in postmenopausal women. • The treatment of osteoporosis in men. For the treatment of osteoporosis, the alendronate sodium component of FOSAVANCE® increases bone mass and can prevent fractures, including those of the hip and spine (vertebral compression fractures). Osteoporosis may be confirmed by the finding of low bone mass (for example, at least 2.5 standard deviations below the premenopausal mean) or by the presence or history of osteoporotic fracture. Patients suffering from osteoporosis are at an increased risk for vitamin D insufficiency, especially those over the age of 70 years, home bound, or chronically ill, and may need to receive vitamin D supplementation in addition to that provided in FOSAVANCE® (see 4.4 DOSAGE AND ADMINISTRATION, Administration). Those living in high latitudes (including most of Canada) may also need additional supplementation. An adequate calcium intake is also required. Patients with gastrointestinal malabsorption may not adequately absorb vitamin D 3 and will also require further supplementation. FOSAVANCE® alone should no… https://pdf.hres.ca/dpd_pm/00071923.PDF PM date: not printed or not captured Source product: FOSAVANCE; DIN 02276429; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.